A Phase 3 interventional study of Teplizumab Herold Regimen and Placebo in Type 1 Diabetes Mellitus, sponsored by MacroGenics. Terminated at 118 sites in 16 countries. Open to participants aged 8 Years to 35 Years. Per ClinicalTrials.gov, last updated 2023-12-20.
Sponsored by MacroGenics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing teplizumab in Diabetes Mellitus, Type 1 — 2 open to participants now, 3 under way, 1 of them phase 3. teplizumab · Diabetes Mellitus, Type 1.
Among the 11 studies testing teplizumab in Diabetes Mellitus, Type 1, this one is the 4th largest by enrollment, is the only one that started in 2009, is one of 3 in phase 3, and was the 3rd registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →2 of the 11 studies testing teplizumab in Diabetes Mellitus, Type 1 are open now, in 12 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Argentina, Australia and 17 more countries
Ages 1–25
Abdullah Kars · Sites in Turkey
Ages 18–45
By country, each count listing its studies:
teplizumab: first FDA approval 2022 (TZIELD), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.
This study: 8 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 4 · Phase 4 1
First in 2002; this study’s year is marked. 1 started in 2009.
This study's enrollment of 254 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 60 across the 11 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 11 have an industry lead sponsor. The 8 most frequent:
MacroGenics is the lead sponsor of 42 studies on the registry; 4 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 11 (65%) have results posted.
MacroGenics has 4 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing teplizumab in Diabetes Mellitus, Type 1, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to determine whether teplizumab (MGA031) infusions lead to greater reductions in insulin requirements in conjunction with near normal blood sugar control compared to placebo in patients recently diagnosed with type 1 diabetes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of T1DM as evidenced by one positive result on testing for any of the following antibodies at screening:
Exclusion Criteria:
Vaccination with a live virus or organism within the 8 weeks before randomization continuing through Week 52 of the study.
14-day cycle of teplizumab consisting of daily IV doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, and 413 µg/m2 on Study Days 1-4, respectively, and one dose of 826 µg/m2 on each of Study Days 5-14. Repeat at Week 26
Biological: Teplizumab Herold Regimen
Subjects received a 14-day cycle of teplizumab consisting of daily IV doses of 17 µg/m2, 34 µg/m2, 68 µg/m2, and 136 µg/m2 on Study Days 1-4, respectively, and one dose of 273 µg/m2 on each of Study Days 5-14. Repeat at Week 26
Biological: Teplizumab 33.3% Herold Regimen
Subjects received a 6 day cycle of teplizumab consisting of daily IV doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, and 413 µg/m2 on Study Days 1-4, respectively, and one dose of 826 µg/m2 on each of Study Days 5-6, followed by 8 days of IV placebo (Study Days 7-14). Repeat at Week 26
Biological: Teplizumab Curtailed Herold Regimen
14-day cycle of placebo consisting of daily IV doses. Repeat at Week 26
Drug: Placebo
Full dose of teplizumab IV for 14 days, repeated at Week 26
Also known as: MGA031
IV dosing daily for 14 days repeated at Week 26
One third full dose of teplizumab IV for 14 days, repeated at Week 26
Also known as: MGA031
Full dose of teplizumab IV for 6 days followed by placebo for 8 days, repeated at Week 26
Proportion of Subjects With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.
Time frame: 52 weeks after randomization
Mean Change From Baseline in HbA1c Between Teplizumab and Placebo
Time frame: 52 weeks after randomization
The Change in Beta-cell Function as Measured by C-peptide Secretory Response Following a Mixed Meal
Time frame: 52 weeks after randomization
The Change in Beta-cell Function as Measured by C-peptide Secretory Response Following a Mixed Meal
Time frame: 104 weeks after randomization
Mean Number of Total, Major, Minor and Nocturnal Hypoglycemia Events
Number of hypoglycemic events by type per participant
Time frame: Throughout the study up to 2 years
Mean Number of Daily Insulin Injections
Time frame: 52 weeks after randomization
Number of Subjects With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%.
Time frame: 104 weeks after randomization
The Proportion of Subjects Who Have Both a Total Daily Insulin Dose < 0.5 U/Kg/Day and Hemoglobin A1c (HbA1c) Level < 7.0%
Time frame: 52 weeks after randomization
The Mean HbA1c Change From Baseline
Time frame: 104 weeks after randomization
Number of Participants With Adverse Events
Time frame: throughout the study, up to 104 weeks
Number of Participants With Serious Adverse Events
Time frame: throughout the study, up to 104 weeks
| Milestone | Herold Regimen | 33.3% Herold Regimen | Curtailed Herold Regimen | Placebo |
|---|---|---|---|---|
| Started | 63 | 66 | 63 | 62 |
| Completed | 50 | 60 | 52 | 57 |
| Not completed | 13 | 6 | 11 | 5 |
| Withdrew: Lost to follow-up | 5 | 1 | 2 | 0 |
| Withdrew: Withdrawal by subject | 5 | 4 | 6 | 3 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 |
| Withdrew: Other | 2 | 1 | 3 | 2 |
| Participants | Herold Regimen | 33.3% Herold Regimen | Curtailed Herold Regimen | Placebo |
|---|---|---|---|---|
| Proportion of Subjects With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%. | 8 | 8 | 9 | 6 |
| percent HbA1c | Herold Regimen | 33.3% Herold Regimen | Curtailed Herold Regimen | Placebo |
|---|---|---|---|---|
| Mean Change From Baseline in HbA1c Between Teplizumab and Placebo | 0.01 ± 1.803 | -0.02 ± 2.169 | 0.35 ± 25.12 | 0.03 ± 2.566 |
| nmol/L | Herold Regimen | 33.3% Herold Regimen | Curtailed Herold Regimen | Placebo |
|---|---|---|---|---|
| The Change in Beta-cell Function as Measured by C-peptide Secretory Response Following a Mixed Meal | 0.04 ± 0.276 | -0.05 ± 0.456 | 0.04 ± 0.287 | -0.04 ± 0.419 |
No measurements were reported for this outcome.
Number of hypoglycemic events by type per participant
| events | Herold Regimen | 33.3% Herold Regimen | Curtailed Herold Regimen | Placebo |
|---|---|---|---|---|
| Total (any) | 13.7 ± 22.35 | 15.9 ± 22.90 | 18.9 ± 41.42 | 15.5 ± 22.70 |
| Minor hypoglycemia | 4.1 ± 6.97 | 4.4 ± 6.38 | 5.4 ± 12.11 | 4.7 ± 10.45 |
| Major hypoglycemia | 10.0 ± 0.13 | 0.1 ± 0.42 | 0.0 ± 0.18 | 0.0 ± 0.13 |
| Nocturnal hypoglycemia | 2.0 ± 3.17 | 2.1 ± 5.54 | 1.4 ± 2.46 | 1.6 ± 3.33 |
No measurements were reported for this outcome.
| Participants | Herold Regimen | 33.3% Herold Regimen | Curtailed Herold Regimen | Placebo |
|---|---|---|---|---|
| Number of Subjects With Both a Total Daily Insulin Dose of Less Than 0.5 U/kg/Day and Hemoglobin A1c (HbA1c) Level of Less Than 6.5%. | 1 | 2 | 1 | 1 |
| Participants | Herold Regimen | 33.3% Herold Regimen | Curtailed Herold Regimen | Placebo |
|---|---|---|---|---|
| The Proportion of Subjects Who Have Both a Total Daily Insulin Dose < 0.5 U/Kg/Day and Hemoglobin A1c (HbA1c) Level < 7.0% | 13 | 10 | 12 | 7 |
| percent glycosylated hemoglobin | Herold Regimen | 33.3% Herold Regimen | Curtailed Herold Regimen | Placebo |
|---|---|---|---|---|
| The Mean HbA1c Change From Baseline | 1.05 ± 2.344 | 1.11 ± 2.494 | 0.71 ± 3.740 | 1.21 ± 2.857 |
| Participants | Herold Regimen | 33.3% Herold Regimen | Curtailed Herold Regimen | Placebo |
|---|---|---|---|---|
| Number of Participants With Adverse Events | 63 | 66 | 63 | 62 |
| Participants | Herold Regimen | 33.3% Herold Regimen | Curtailed Herold Regimen | Placebo |
|---|---|---|---|---|
| Number of Participants With Serious Adverse Events | 7 | 6 | 8 | 3 |
Collected over Throughout the study, up to 2 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Herold Regimen | 0/63 (0%) | 7/63 (11.1%) | 63/63 (100%) |
| 33.3% Herold Regimen | 0/66 (0%) | 6/66 (9.1%) | 66/66 (100%) |
| Curtailed Herold Regimen | 0/63 (0%) | 8/63 (12.7%) | 63/63 (100%) |
| Placebo | 0/62 (0%) | 3/62 (4.8%) | 62/62 (100%) |
| Event | Herold Regimen | 33.3% Herold Regimen | Curtailed Herold Regimen | Placebo |
|---|---|---|---|---|
| Diabetic ketoacidosisMetabolism and nutrition disorders | 1/63 | 1/66 | 3/63 | 0/62 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/63 | 0/66 | 0/63 | 2/62 |
| Hypoglycaemic seizureMetabolism and nutrition disorders | 0/63 | 1/66 | 2/63 | 0/62 |
| GastroenteritisInfections and infestations | 0/63 | 0/66 | 0/63 | 1/62 |
| LymphopeniaBlood and lymphatic system disorders | 1/63 | 0/66 | 1/63 | 0/62 |
| Abdominal painGastrointestinal disorders | 1/63 | 0/66 | 0/63 | 0/62 |
| GastritisGastrointestinal disorders | 0/63 | 0/66 | 1/63 | 0/62 |
| Cytokine release syndromeImmune system disorders | 1/63 | 1/66 | 0/63 | 0/62 |
| Hepatic amoebiasisInfections and infestations | 0/63 | 0/66 | 1/63 | 0/62 |
| PyelonephritisInfections and infestations | 1/63 | 0/66 | 0/63 | 0/62 |
| Event | Herold Regimen | 33.3% Herold Regimen | Curtailed Herold Regimen | Placebo |
|---|---|---|---|---|
| White blood cell count decreasedInvestigations | 39/63 | 28/66 | 29/63 | 13/62 |
| Blood bicarbonate decreasedInvestigations | 31/63 | 38/66 | 27/63 | 26/62 |
| Lymphocyte count decreasedInvestigations | 35/63 | 32/66 | 33/63 | 6/62 |
| LymphopeniaBlood and lymphatic system disorders | 26/63 | 21/66 | 25/63 | 6/62 |
| Haemoglobin decreasedInvestigations | 23/63 | 20/66 | 22/63 | 17/62 |
| Neutrophil count decreasedInvestigations | 23/63 | 16/66 | 23/63 | 10/62 |
| Aspartate aminotransferase increasedInvestigations | 20/63 | 15/66 | 22/63 | 11/62 |
| PyrexiaGeneral disorders | 14/63 | 12/66 | 20/63 | 7/62 |
| Alanine aminotransferase increasedInvestigations | 20/63 | 14/66 | 19/63 | 6/62 |
| Blood calcium decreasedInvestigations | 20/63 | 13/66 | 8/63 | 11/62 |
| Age, Continuous(years) | Herold Regimen | 33.3% Herold Regimen | Curtailed Herold Regimen | Placebo | Total |
|---|---|---|---|---|---|
| Median | 16.0 (8.0 to 23.0) | 16.0 (8.0 to 35.0) | 15.0 (8.0 to 33.0) | 16.0 (9.0 to 35.0) | 16.0 (8.0 to 35.0) |
| Age, Customized(Participants) | Herold Regimen | 33.3% Herold Regimen | Curtailed Herold Regimen | Placebo | Total |
|---|---|---|---|---|---|
| 8-11 years | 13 | 12 | 13 | 11 | 49 |
| 12-17 years | 24 | 29 | 24 | 25 | 102 |
| 18-35 years | 26 | 25 | 26 | 26 | 103 |
| Sex: Female, Male(Participants) | Herold Regimen | 33.3% Herold Regimen | Curtailed Herold Regimen | Placebo | Total |
|---|---|---|---|---|---|
| Female | 25 | 20 | 17 | 21 | 83 |
| Male | 38 | 46 | 46 | 41 | 171 |
| Ethnicity (NIH/OMB)(Participants) | Herold Regimen | 33.3% Herold Regimen | Curtailed Herold Regimen | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 | 4 | 6 |
| Not Hispanic or Latino | 63 | 65 | 62 | 58 | 248 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Herold Regimen | 33.3% Herold Regimen | Curtailed Herold Regimen | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 25 | 26 | 25 | 23 | 99 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 3 | 2 | 5 |
| White | 36 | 39 | 35 | 37 | 147 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 1 | 0 | 0 | 3 |
| Region of Enrollment(participants) | Herold Regimen | 33.3% Herold Regimen | Curtailed Herold Regimen | Placebo | Total |
|---|---|---|---|---|---|
| Romania | 3 | 3 | 1 | 3 | 10 |
| United States | 17 | 17 | 17 | 17 | 68 |
| Czechia | 4 | 5 | 6 | 5 | 20 |
| Ukraine | 5 | 5 | 4 | 6 | 20 |
| United Kingdom | 0 | 0 | 1 | 0 | 1 |
| India | 25 | 26 | 25 | 23 | 99 |
| Spain | 1 | 2 | 2 | 2 | 7 |
| Belgium | 1 | 0 | 0 | 0 | 1 |
| Finland | 0 | 1 | 0 | 0 | 1 |
| Poland | 3 | 2 | 2 | 2 | 9 |
| Mexico | 0 | 0 | 0 | 1 | 1 |
| Israel | 3 | 3 | 4 | 2 | 12 |
| Germany | 1 | 2 | 1 | 1 | 5 |
Showing the first 100 of 118 sites across 16 countries. Choose a country and city above to see the rest.
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Sep 2009, a primary completion of Apr 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2023, 11 years 8 months after primary completion. A results delay was requested in Feb 2013.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teplizumab